eyeforpharma Philadelphia 2017: 6 in-depth conferences in one

eyeforpharma20 - 21 April 2017, Philadelphia, USA.
The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond, the 6 eyeforpharma Philadelphia 2017 sessions will focus on:

Commercial Leadership

  • Commercial Leadership: Healthcare Leadership: How Pharma Embraces a New Customer Engagement Paradigm
  • Executive Commitment: Recognize Patient Centricity as a Journey: and Spearhead Cultural Change
  • Business Transformation: Your Company Needs to be Disrupted: Corporate Activism for Value Creation
  • Technology Partnerships: Tech meets Pharma: Life Science Partnerships from Bench to Bedside
  • Healthcare Challenges: Approaching the Caregiver Cliff: How Pharma Should Support the Supporters
  • The Implementation Panel: From Words to Action, How to Become a Pharma Intrapreneur

Patients as Partners

  • Patient advocacy 2.0: Manage ‘local customer engagement' from pre to post launch
  • The future of pharma-stakeholder collaboration: Lessons learnt from partnering in the rare disease field
  • Where rubber hits the road: Can patient centricity grow the bottom-line?
  • Case studies on understanding and acting on patient concern

Customer Experience

  • Is the new sales strategy to de-prioritize targets?
  • Customer experience is the key to commercial excellence
  • It's the experience that counts!
  • Look after your customer's journey from start to finish
  • Sales rep 2.0: The new portrait of a customer facing role

Commercial Model Innovation

  • A holistic commercial view: integrate your sales and marketing teams
  • Leverage untapped opportunities with patient-centric selling
  • Customer centricity is key. Are you doing enough?
  • The Modern Marketer: how to stay ahead in a competitive landscape

Pharma's Triple Aim

  • Strengthen the patient ecosystem - improve treatment adherence beyond physician support
  • How to innovate and differentiate your patient assistance solutions
  • Understand factors driving patients' treatment choices
  • Free your engagement from uncertainty around compliance

Digital Transformation

  • Maximize capabilities of your commercial teams with technology
  • Stay ahead of the curve: How digital integration takes your customer’s experience further
  • The power of integrating digital across all aspects of your organization
  • Leveraging Digital: Navigating digital trends and technologies to maximize positive outcomes for patients

Join the most forward thinking speakers from across North America including C-level, VPs and industry leaders from Shire, Otsuka, GSK, Novartis, Pfizer, Google, Sanofi, Takeda and many more. This is the ideal place to ensure your commercial strategy is prepared for 2017 and beyond.

World Pharma News readers can benefit from an exclusive discount - save $200 using our unique discount code WPN200 when you register online.

You can find full details of the meeting here.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...